Skip to main content
PMC home page
Frontiers in Psychiatry logoLink to Frontiers in Psychiatry
. 2018 May 31;9:207. doi: 10.3389/fpsyt.2018.00207

Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder

Céline S Reinbold 1,2,†, Andreas J Forstner 1,2,3,4,5,†, Julian Hecker 6, Janice M Fullerton 7,8, Per Hoffmann 1,2,3,4, Liping Hou 9, Urs Heilbronner 10, Franziska Degenhardt 3,4, Mazda Adli 11, Kazufumi Akiyama 12, Nirmala Akula 9, Raffaella Ardau 13, Bárbara Arias 14, Lena Backlund 15, Antonio Benabarre 16, Susanne Bengesser 17, Abesh K Bhattacharjee 18, Joanna M Biernacka 19,20, Armin Birner 17, Cynthia Marie-Claire 21,22, Pablo Cervantes 23, Guo-Bo Chen 24, Hsi-Chung Chen 25, Caterina Chillotti 13, Scott R Clark 26, Francesc Colom 27, David A Cousins 28, Cristiana Cruceanu 29, Piotr M Czerski 30, Alexandre Dayer 31, Bruno Étain 21,22,32, Peter Falkai 33, Louise Frisén 15, Sébastien Gard 34, Julie S Garnham 35, Fernando S Goes 36, Paul Grof 37, Oliver Gruber 38, Ryota Hashimoto 39, Joanna Hauser 30, Stefan Herms 1,2,3,4, Stéphane Jamain 40, Esther Jiménez 16, Jean-Pierre Kahn 41, Layla Kassem 9, Sarah Kittel-Schneider 42, Sebastian Kliwicki 43, Barbara König 44, Ichiro Kusumi 45, Nina Lackner 17, Gonzalo Laje 9, Mikael Landén 46,47, Catharina Lavebratt 15, Marion Leboyer 48, Susan G Leckband 49, Carlos A López Jaramillo 50, Glenda MacQueen 51, Mirko Manchia 52,53, Lina Martinsson 54, Manuel Mattheisen 55, Michael J McCarthy 56, Susan L McElroy 57, Marina Mitjans 14, Francis M Mondimore 36, Palmiero Monteleone 58,59, Caroline M Nievergelt 18, Urban Ösby 60, Norio Ozaki 61, Roy H Perlis 62, Andrea Pfennig 63, Daniela Reich-Erkelenz 10, Guy A Rouleau 64, Peter R Schofield 8,65, K Oliver Schubert 26, Barbara W Schweizer 36, Florian Seemüller 33, Giovanni Severino 66, Tatyana Shekhtman 18, Paul D Shilling 18, Kazutaka Shimoda 67, Christian Simhandl 68,69, Claire M Slaney 35, Jordan W Smoller 62, Alessio Squassina 66, Thomas J Stamm 11,70, Pavla Stopkova 71, Sarah K Tighe 72, Alfonso Tortorella 59, Gustavo Turecki 29, Julia Volkert 42, Stephanie H Witt 73, Adam J Wright 74, L Trevor Young 75, Peter P Zandi 76, James B Potash 72, J Raymond DePaulo 36, Michael Bauer 63, Eva Reininghaus 17, Tomáš Novák 71, Jean-Michel Aubry 31, Mario Maj 59, Bernhard T Baune 26, Philip B Mitchell 74, Eduard Vieta 16, Mark A Frye 20, Janusz K Rybakowski 43, Po-Hsiu Kuo 77, Tadafumi Kato 78, Maria Grigoroiu-Serbanescu 79, Andreas Reif 42, Maria Del Zompo 66, Frank Bellivier 21,22,32, Martin Schalling 15, Naomi R Wray 24, John R Kelsoe 18, Martin Alda 35,71, Francis J McMahon 9, Thomas G Schulze 9,10,36,38,73, Marcella Rietschel 73, Markus M Nöthen 3,4, Sven Cichon 1,2,3,4,80,*
PMCID: PMC5991073  PMID: 29904359

Abstract

Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGen GWAS dataset (n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait (p = 9.80E-04) and miR-607 with the dichotomous phenotype (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted.

Keywords: bipolar disorder, lithium response, microRNA, common variants, genome-wide association study

Introduction

Bipolar disorder (BD) is a severe neuropsychiatric condition categorized by recurrent episodes of depression and mania. BD is common, with a lifetime prevalence of around 1% in the general population (1). The elevated morbidity and mortality, the typically early age at onset in young adulthood and the chronic course of BD make it a major public health problem, and BD is classified as one of the top 25 leading causes of the global burden of disease (2). Epidemiological and molecular genetic data strongly suggest that BD is a complex disorder (3) which means that both genetic and environmental factors influence illness risk. Based on twin studies the overall heritability of BD has been estimated to be over 70% (4, 5), suggesting a substantial involvement of genetic factors in the development of the disease.

Mood stabilizers are used as the first-line mode of medication in the treatment of BD (6). Amongst these drugs, lithium is used as a preventive agent for manic and depressive episodes (7), suicide attempts, and death by suicide, and shows the greatest support for long-term relapse prevention (8, 9). Consequently, lithium is endorsed as a first-line and best-established long-term treatment for BD, even though individual response is highly variable (6, 8, 10). Evidence suggests that some of the variability in lithium response has a genetic basis (11, 12). This hypothesis is supported by the largest genome-wide association study (GWAS) of lithium response to date, which was conducted by the International Consortium on Lithium Genetics (ConLiGen) (13, 14). The study investigated genomic data of 2,563 BD patients, identifying a genome-wide significant locus on chromosome 21, which contains two long, non-coding RNA genes (lncRNAs) (14).

Non-coding RNAs (ncRNAs) are transcribed from DNA but do not encode protein, and are involved in complex mechanisms of gene regulation, particularly in fine regulation of the timing and level of expression of their target genes. Another class of ncRNAs whose role in the pathophysiology of psychiatric disorders is emerging, is that of microRNAs (miRNAs). miRNAs are short RNA molecules, which in the mature processed form are 21 to 25-nucleotides in length, that work as post-transcriptional regulators of gene expression (15). To create a mature miRNA, a primary miRNA (pri-miRNA, typically >1,000 nucleotides in length) is first transcribed, and forms a secondary structure through self-base pairing (16, 17). This is cleaved by the Drosha-DiGeorge syndrome critical region gene 8 (Drosha-DGCR8) complex to create a pre-miRNA of around 70 nucleotides (16). This double stranded RNA is exported from the nucleus, cleaved by Dicer-transactivation-responsive RNA-binding protein (Dicer-TRBP) to form the mature miRNA (16), which can then target complementary messenger RNA (mRNA) transcripts through the RNA-induced silencing complex (RISC) to regulate expression (e.g., via mRNA degradation or translational repression) (18). Several studies have reported that miRNAs are potential predictors of treatment response in complex genetic disorders (19–21) including lithium response in BD (22). Furthermore, miRNAs are implicated in biological pathways that regulate brain development and synaptic plasticity (23, 24). Indeed, miR-137 has emerged as a key risk gene in schizophrenia, and is known to regulate the expression of several genes that are independently associated with schizophrenia (25, 26). This implies the potential involvement of miRNAs in the pathogenesis of psychiatric disorders including BD. This hypothesis is further supported by the results of a large GWAS of BD (27) where a single-nucleotide polymorphism (SNP) flanking miR-2113 was amongst the strongest findings.

Our group performed the first genome-wide analysis of the involvement of miRNAs in the development of BD, in a sample of 9,747 patients and 14,278 controls (28) in which we identified nine BD-associated miRNAs that withstood stringent Bonferroni-correction for multiple testing. However, it is largely unknown whether these miRNAs are also associated with lithium response in BD.

Therefore, the aim of the present study was to determine whether common variants at any of the nine BD-associated miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA is implicated in the response to lithium. For this purpose, we performed window-based association testing for all known miRNA coding genes in the largest GWAS dataset of lithium response so far.

Materials and methods

Sample description

Analyses were performed using summary statistics from the previously published GWAS of lithium response in BD patients (n = 2,563 patients) (14). These GWAS datasets were collected by ConLiGen and combine imputed genotype data from 22 contributing sites from four continents (Europe, America, Asia, and Australia). The study was approved by the respective local ethics committees. Written informed consent was obtained from all participants prior to inclusion. The Alda scale was used to create a dichotomous (good vs. poor response to lithium) and a continuous measure (range 0–10) for the evaluation of long-term treatment response to lithium. Briefly, the Alda scale measures symptom improvement in the course of lithium treatment (A score, range 0–10), which is then weighted against five criteria (B score) that assess confounding factors, each scored 0, 1, or 2. The total score is calculated by subtracting the total B score from the A score. Negative scores are set to 0 by default leading to a total score range from 0 to 10. For the purpose of the present analysis, subjects with a total score of 7 or higher were defined as showing “good response” to lithium treatment in the dichotomous phenotype. As continuous measurement, we used the A score, but excluded all individuals with a total B score greater than 4, as continuous measure (14, 29).

Definition of candidate and genome-wide miRNAs

Information on the nine BD-associated miRNAs was obtained from our previously published genome-wide analysis of miRNAs in BD (28). The chromosomal positions of the miRNAs were obtained from the miRBase database (release 21) (30).

For the genome-wide miRNA association analysis chromosomal positions for all 1,871 remaining miRNAs were obtained from miRBase (release 21). miRNAs which were not located on autosomal chromosomes (n = 120) were removed from further analysis. Only miRNA genes which were covered in the summary statistics of lithium response were included, resulting in 1,692 miRNAs which were tested in the genome-wide analysis. For each gene, the entire preprocessed transcript ± 20 kilobase (kb) flanking sequence were analyzed, which would include the majority of the regulatory regions (17).

MiRNA-based association tests

For the gene-based tests, we applied a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2) (31, 32) with a minor correction for the top-0.1-test option (33). This algorithm is obtainable upon request. The top-0.1-test was used since it showed the highest sensitivity with less than 1% false positives across a variety of investigated gene-level methods (34). The applied statistical algorithm is described in more detail in the article by Mishra and Macgregor (32). Briefly, we grouped SNPs within the miRNA loci ± 20 kb flanking sequence together and calculated a set-based test statistic as the sum of the χ2 one degree of freedom association P-values within the miRNA. The observed test statistic was compared with simulated test statistics from the multivariate normal distribution with correlation equal to the corresponding LD structure as derived from the 1,000 Genomes phase 3 European population genotypes (35, 36). We calculated an empirical miRNA-based P-value as the proportion of simulated test statistics above the observed test statistic. For the purposes of the present study, we used the top-0.1-test option which summarizes the 10% most significant SNPs for each miRNA.

Using the two summary statistics, miRNA-based P-values were calculated for all miRNAs. The calculated miRNA-based P-values were corrected for multiple testing according to Benjamini-Hochberg.

Enrichment tests

To test whether nominally significant SNPs were enriched within miRNAs and their flanking regions, we conducted the Fisher's Exact Test for each summary statistic separately. Additionally, we tested whether the number of cis-miR-eQTL SNPs identified by Huan et al. (37) with a p-value of < 0.05 was higher than expected using the Fisher's Exact Test.

Results

Of the nine tested BD-associated miRNAs, miR-499a showed nominally significant P-values in both datasets (dichotomous and continuous treatment response, Table 1). Of the remaining 1,692 miRNAs tested for the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous and 106 with the continuous treatment response. Fifteen miRNAs revealed nominal significance with both phenotypes. miR-633 showed the strongest association with the continuous phenotype (p = 9.80E-04). Regarding the dichotomous phenotype, miR-607 showed the strongest association (p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction (Tables 1, 2).

Table 1.

Results of the window-based tests for the nine BD-associated miRNAs.

miRNA [position] n SNPs p miRNA pcorr miRNA Top SNP [position] p Top SNP
A) Dichotomous Treatment Response Measure
miR-499a [chr20:34990376-34990497] 87 1.71E-02 9.31E-01 rs117616040 [chr20:34977725] 2.27E-03
miR-135a-1 [chr3:52294219-52294308] 41 9.29E-02 9.31E-01 rs699465 [chr3:52276426] 1.98E-02
let-7g [chr3:52268278-52268361] 44 1.04E-01 9.31E-01 rs699465 [chr3:52276426] 1.98E-02
miR-644a [chr20:34466325-34466418] 35 2.03E-01 9.37E-01 rs7266300 [chr20:34449603] 9.76E-03
miR-708 [chr11:79402022-79402109] 130 3.51E-01 9.50E-01 rs12275848 [chr11:79416285] 7.89E-02
miR-1908 [chr11:61815161-61815240] 39 4.33E-01 9.50E-01 rs61897792 [chr11:61819414] 3.46E-02
miR-640 [chr19:19435063-19435158] 44 6.08E-01 9.55E-01 rs79954596 [chr19:19437834] 1.74E-01
miR-611 [chr11:61792495-61792561] 33 6.36E-01 9.55E-01 rs17762402 [chr11:61785729] 4.94E-02
miR-581 [chr5:53951504-53951599] 55 6.41E-01 9.55E-01 rs72644081 [chr5:53949850] 5.45E-02
B) Continuous Treatment Response Measure
miR-499a [chr20:34990376-34990497] 87 3.18E-02 7.52E-01 rs117616040 [chr20:34977725] 3.73E-03
miR-708 [chr11:79402022-79402109] 130 7.37E-02 8.02E-01 rs1355423 [chr11:79420556] 2.05E-02
miR-611 [chr11:61792495-61792561] 33 9.79E-02 8.22E-01 rs174532 [chr11:61781402] 3.30E-03
miR-644a [chr20:34466325-34466418] 35 1.95E-01 8.50E-01 rs7266300 [chr20:34449603] 6.47E-02
miR-1908 [chr11:61815161-61815240] 39 2.45E-01 8.64E-01 rs968567 [chr11:61828092] 3.20E-02
miR-640 [chr19:19435063-19435158] 45 2.69E-01 9.52E-01 rs79954596 [chr19:19437834] 1.15E-02
let-7g [chr3:52268278-52268361] 44 6.40E-01 9.81E-01 rs58315325 [chr3:52261812] 2.80E-02
miR-135a-1 [chr3:52294219-52294308] 41 7.81E-01 9.86E-01 rs34135146 [chr3:52279416] 6.28E-02
miR-581 [chr5:53951504-53951599] 55 9.22E-01 7.52E-01 rs697112 [chr5:53964849] 1.61E-01
Open in a new tab

microRNAs (miRNAs) are sorted according to their miRNA-based P-value. Genome build used is GRCh38 (hg38). Abbreviations: miRNA, microRNA; position, genomic position; nSNPs, number of investigated SNPs; p miRNA, miRNA-based P-value; pcorr miRNA, Benjamini-Hochberg corrected miRNA-based P-value; Top SNP, top single-nucleotide polymorphism within gene; p Top SNP, P-value of the Top SNP within gene.

Table 2.

Results of the window-based tests for the top five genome-wide miRNAs.

miRNA [position] n SNPs p miRNA pcorr miRNA Top SNP [position] p Top SNP
A) Dichotomous Treatment Response Measure
miR-607 [chr10:96828669-96828764] 48 5.79E-04 9.31E-01 rs111682442 [chr10:96823685] 2.73E-04
miR-8085 [chr19:44758657-44758721] 44 2.54E-03 9.31E-01 rs7249244 [chr19:44742441] 1.11E-04
miR-1296 [chr10:63372957-63373048] 62 4.13E-03 9.31E-01 rs10995527 [chr10:63387659] 5.47E-03
miR-4535 [chr22:48780295-48780353] 160 4.62E-03 9.31E-01 rs131016 [chr22:48775746] 1.24E-03
miR-451b [chr17:28861371-28861438] 44 5.11E-03 9.31E-01 rs34901720 [chr17:28852500] 2.17E-03
B) Continuous Treatment Response Measure
miR-633 [chr17:62944215-62944312] 29 9.80E-04 7.52E-01 rs1588368 [chr17:62938848] 1.21E-04
miR-6516 [chr17:77089417-77089497] 183 1.97E-03 8.02E-01 rs2411054 [chr17:77074245] 2.68E-05
miR-218-1 [chr4:20528275-20528384] 105 2.13E-03 8.22E-01 rs540146 [chr4:20544433] 6.08E-04
miR-7704 [chr2:176188843-176188901] 68 2.20E-03 8.50E-01 rs7589870 [chr2:176208720] 1.26E-03
miR-548e [chr10:110988926-110989013] 54 2.48E-03 8.64E-01 rs1327551 [chr10:111008438] 1.09E-03
Open in a new tab

microRNAs (miRNAs) are sorted according to their miRNA-based P-value. Genome build used is GRCh38 (hg38). Abbreviations: miRNA, microRNA; position, genomic position; nSNPs, number of investigated SNPs; p miRNA, miRNA-based P-value; pcorr miRNA, Benjamini-Hochberg corrected miRNA-based P-value; Top SNP, top single-nucleotide polymorphism within gene; p Top SNP, P-value of the Top SNP within gene.

The number of nominally significant SNPs in both of our GWAS of lithium response located at miRNA loci (n = 6,321 and n = 5,742 for continuous and dichotomous measurement, respectively) was not significantly higher than expected (p = 9.96E-01 and p = 1 for continuous and dichotomous measurement, respectively, Fisher's Exact Test).

The number of cis-miR-eQTL SNPs [identified by Huan et al. (37) in our summary statistics (n = 341 and n = 318 for continuous and dichotomous measurement, respectively) were significantly higher than expected (p = 3.31E-05 and p = 6.23E-03 for continuous and dichotomous measurement, respectively, Fisher's Exact Test).

Discussion

The current study investigated whether common variants at BD-associated miRNA, or any other miRNA loci, contribute to the differences in lithium response in BD patients.

miR-499a showed a nominally significant association with lithium response in the candidate approach. Although the association did not withstand correction for multiple testing, this result provides some evidence that miR-499a might be involved in both development and treatment of BD. A previous study has shown an upregulation of this miRNA in the prefrontal cortex of patients with depression (38). In another study, miR-499a was differentially expressed in the postmortem brains of BD patients compared with controls (39). Furthermore, a recent study by Banach et al. (40) reported lower expression levels of miR-499 in the peripheral blood of BD patients during depressive episodes in comparison to remission, suggesting miR-499 as a potential new biomarker of illness state in BD.

Overall, the results of our candidate approach do not suggest that individual BD-associated miRNAs might have a strong influence on differential responses to lithium treatment in BD as no association withstood multiple testing correction. On the one hand, this might at least in part reflect that the power to detect associations between common variants and lithium response was limited in the present study, even though the ConLiGen GWAS comprised several thousand individuals (41). On the other hand, it might also indicate that the genetic factors that contribute to BD etiology are different from those contributing to treatment response or illness course. That there are such effects in multifactorial diseases is supported by a study in ulcerative colitis in which no SNPs from 163 inflammatory bowel disease susceptibility loci (42) were found to be associated with the disease course (43).

In our systematic, genome-wide analysis of miRNAs, 106 miRNAs revealed nominally significant associations with the continuous and 71 with the dichotomous lithium treatment response.

The intergenic miR-633 located on chromosome 17 showed the strongest association with the continuous phenotype (p = 9.80E-04). To date, few published studies have investigated the function of miR-633. Interestingly, one study reported that miR-633 was differentially regulated in the cerebrospinal fluid of patients with multiple sclerosis compared to patients with other neurologic diseases. In addition, miR-633 differentiated relapsing-remitting from secondary progressive multiple sclerosis courses suggesting this miRNA as a potential biomarker for disease course in multiple sclerosis (44).

miR-607, an intergenic miRNA located upstream of the ligand dependent nuclear receptor corepressor (LCOR) gene on chromosome 10, displayed the strongest association with the dichotomous treatment response measure (p = 5.79E-04). The function of this miRNA has been poorly characterized so far, so that we cannot currently speculate about possible disease- and treatment-relevant biological processes. Further research is needed to elucidate the potential role of miR-607 in health or disease.

No association between miRNAs and BD treatment response to lithium in either of the tested conditions withstood multiple testing correction. In addition, we did not observe a significant enrichment for SNPs at all microRNA loci in the present study. Given the limited power of our study, future investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted as better understanding of genetic factors contributing to disease etiology and treatment response might enable the individualization of treatment as well as the identification of novel therapeutic targets (45).

In the present study, we investigated all currently known miRNAs regardless of their tissue or developmental expression patterns. Approximately 70% of ncRNAs are thought to be brain expressed (23) and are dynamically regulated during development and over the lifespan. While the exact mechanisms by which lithium exerts its therapeutic effects remain unclear, pharmacokinetics and pharmacodynamics highlight the importance of specific tissues (e.g., brain and kidney) in treatment responsiveness (46, 47). Therefore, an analysis including miRNAs expressed specifically in these tissues would seem to be a rational follow-up step to reduce the multiple testing burden and to narrow-down the miRNAs to those that a priori may have a greater chance to be involved in lithium response. Unfortunately, a systematic enrichment analyses for miRNAs in particular tissues would be premature, since there are currently no comprehensive expression databases derived from normal tissue covering all known miRNAs investigated in the present study. Data on miRNA expression at various developmental stages is also still limited, as non-polyadenylated transcripts are typically not captured with standard library preparation for RNA sequencing. Furthermore, some miRNAs may only be expressed during early developmental stages but can still have an influence on lithium response later on in life, particularly if expression is induced by pharmaceutical treatment. Nevertheless, these aspects remain important and should be considered in future analyses as soon as more comprehensive data on miRNA expression become available.

Using the present approach, we were not able to investigate SNPs with trans-expression quantitative trait loci (eQTL) effects on miRNAs. Previous studies suggest that a substantial proportion of the identified miR-eQTLs are trans-eQTLs (48). Therefore, future investigations into the molecular interactions underlying the association between miRNA trans-eQTLs and treatment response to lithium in BD are also warranted. Huan et al. (37) conducted a genome-wide miR-eQTL mapping study and found consistent evidence for 5,269 cis-miR-eQTLs for 76 mature microRNAs. The significant enrichment for cis-miR-eQTL SNPs found in our summary statistics provides some evidence for the importance of cis-miR-eQTLs in lithium response, although we were not able to identify cis-miR-eQTL SNPs in our top findings since those miRNAs were not among the 76 mature microRNAs reported by Huan et al. (37).

Moreover, miRNAs only represent one class of non-coding RNAs. In the ConLiGen GWAS a genome-wide significant locus containing two lncRNAs was identified (14). Further analyses on the contribution of lncRNAs to lithium response are therefore warranted. This was beyond the scope of the present analysis as the current understanding of the predicted structure of lncRNA molecules and their biological functions remains limited (49).

In conclusion, our analyses do not provide strong evidence that miRNAs are involved in individual response to lithium treatment in BD, as no association between miRNAs and lithium response withstood multiple testing correction. Our data should still be interesting for follow-up of independent studies, particularly when sufficient data is available to accurately define the tissue and temporal expression profile of all human miRNAs, which would allow a more targeted analysis of brain-expressed miRNAs, thereby reducing the search space to miRNAs with relevant expression profiles. We did not find any strong effect that could be useful in terms of a personalized treatment for individual patients. This does not exclude a possible (small) effect of miRNAs on lithium response, and further independent and even larger studies should be envisaged to clarify this question. In parallel, the investigation of other biological mechanisms possibly contributing to lithium treatment response may provide insights for individualizing future pharmacotherapy in BD.

Author contributions

CR, AF, MN, and SC contributed to the conception and design of the study. AF, LH, UH, FD, MA, KA, NA, RA, BA, LB, AB, SB, AKB, JB, ABi, CM-C, PC, G-BC, H-CC, CC, SRC, FC, DC, CCr, PMC, AD, BE, PF, LF, JF, SG, JG, FG, PG, OG, RH, JHa, SH, SJ, EJ, J-PK, LK, SK-S, SK, BK, IK, NL, GL, ML, CL, MLe, SL, CAL, GM, MM, LM, MMa, MJM, SM, MMi, FM, PM, CN, UÖ, NO, RP, AP, DR-E, GR, PRS, KOS, BS, FS, GS, TS, PDS, KS, CS, CMS, JS, AS, TSt, PS, ST, AT, GT, JV, SW, AW, LY, PZ, JP, JD, MB, ER, TN, J-MA, MMaj, BB, PM, EV, MF, JR, P-HK, TK, MG-S, AR, MD, FB, MS, NW, JK, MAl, FM, TGS, MR, and MN recruited the patients and contributed genotype data. CR and JH performed the statistical analysis. CR, AF, MR, MN, and SC prepared the manuscript, with feedback from the other authors. All authors contributed to manuscript revision, read and approved the submitted version.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We are grateful to all patients and control subjects for their participation. We thank the International Consortium on Lithium Genetics (ConLiGen) for providing access to the relevant data.

Footnotes

Funding. The study was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grant 01ZX1314A/01ZX1614A to MN and SC, grant 01ZX1314G/01ZX1614G to MR). The study was also supported by the German Research Foundation (DFG; grant FOR2107; RI908/11-1 to MR; NO246/10-1 to MN), and the Swiss National Science Foundation (SNSF, grant 310030_156791 to SC). MMN is a member of the DFG-funded Excellence-Cluster ImmunoSensation. AF received support from the BONFOR program of the Medical Faculty of the University of Bonn. The collection of the Geneva sample was supported by the Swiss National Foundation (grants Synapsy 51NF40-158776 and 32003B-125469). The Australian sample contribution was supported by the Australian National Health and Medical Research Council (grants 1037196, 1063960) and the Janette Mary O'Neil Research Fellowship to JF.

References

  • 1.Craddock N, Sklar P. Genetics of bipolar disorder. Lancet (2013) 381:1654–62. 10.1016/S0140-6736(13)60855-7 [DOI] [PubMed] [Google Scholar]
  • 2.GBD 2016. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (2017) 390:1211–59. 10.1016/s0140-6736(17)32154-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 373:234–9. 10.1016/S0140-6736(09)60072-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry (2003) 60:497–502. 10.1001/archpsyc.60.5.497 [DOI] [PubMed] [Google Scholar]
  • 5.Edvardsen J, Torgersen S, Røysamb E, Lygren S, Skre I, Onstad S, et al. Heritability of bipolar spectrum disorders. Unity or heterogeneity? J Affect Disord. (2008) 106:229–40. 10.1016/j.jad.2007.07.001 [DOI] [PubMed] [Google Scholar]
  • 6.Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet (2013) 381:1672–82. 10.1016/S0140-6736(13)60857-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry (2004) 161:217–22. 10.1176/appi.ajp.161.2.217 [DOI] [PubMed] [Google Scholar]
  • 8.Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry (2003) 64:(Suppl. 5), 44–52. [PubMed] [Google Scholar]
  • 9.Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry (2005) 162:1805–19. 10.1176/appi.ajp.162.10.1805 [DOI] [PubMed] [Google Scholar]
  • 10.Garnham J, Munro A, Slaney C, MacDougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. (2007) 104:185–90. 10.1016/j.jad.2007.03.003 [DOI] [PubMed] [Google Scholar]
  • 11.Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry (2002) 63:942–7. 10.4088/JCP.v63n1013 [DOI] [PubMed] [Google Scholar]
  • 12.Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. (2005) 7:404–17. 10.1111/j.1399-5618.2005.00244.x [DOI] [PubMed] [Google Scholar]
  • 13.Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology (2010) 62:72–8. 10.1159/000314708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet (2016) 387:1085–93. 10.1016/S0140-6736(16)00143-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Godnic I, Zorc M, Jevsinek Skok D, Calin GA, Horvat S, Dovc P, et al. Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken. PLoS ONE (2013) 8:e65165. 10.1371/journal.pone.0065165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. (2010) 11:597–610. 10.1038/nrg2843 [DOI] [PubMed] [Google Scholar]
  • 17.Wang G, Wang Y, Shen C, Huang Y-W, Huang K, Huang TH, et al. RNA polymerase II binding patterns reveal genomic regions involved in MicroRNA gene regulation. PLoS ONE (2010) 5:e13798. 10.1371/journal.pone.0013798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell (2005) 123:631–40. 10.1016/j.cell.2005.10.022 [DOI] [PubMed] [Google Scholar]
  • 19.Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother. (2016) 84:592–600. 10.1016/j.biopha.2016.09.087 [DOI] [PubMed] [Google Scholar]
  • 20.Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, Lopez-Urrutia E, et al. Micro-RNAs as potential predictors of response to breast cancer systemic therapy: future clinical implications. Int J Mol Sci. (2017) 18:E1182. 10.3390/ijms18061182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Liu Q, Wu DH, Han L, Deng JW, Zhou L, He R, et al. Roles of microRNAs in psoriasis: immunological functions and potential biomarkers. Exp Dermatol. (2017) 26:359–67. 10.1111/exd.13249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hunsberger JG, Chibane FL, Elkahloun AG, Henderson R, Singh R, Lawson J, et al. Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Transl Psychiatry (2015) 5:e504. 10.1038/tp.2014.139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Fineberg SK, Kosik KS, Davidson BL. MicroRNAs potentiate neural development. Neuron (2009) 64:303–9. 10.1016/j.neuron.2009.10.020 [DOI] [PubMed] [Google Scholar]
  • 24.Schratt G. microRNAs at the synapse. Nat Rev Neurosci. (2009) 10:842–9. 10.1038/nrn2763 [DOI] [PubMed] [Google Scholar]
  • 25.The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium Genome-wide association study identifies five new schizophrenia loci. Nat Genet. (2011) 43:969 10.1038/ng.940 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature (2014) 511:421–7. 10.1038/nature13595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. (2014) 5:3339. 10.1038/ncomms4339 [DOI] [PubMed] [Google Scholar]
  • 28.Forstner AJ, Hofmann A, Maaser A, Sumer S, Khudayberdiev S, Mühleisen TW, et al. Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. Transl Psychiatry (2015) 5:e678. 10.1038/tp.2015.159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Manchia M, Adli M, Akula N, Ardau R, Aubry J.-M, Backlund L, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE (2013) 8:e65636. 10.1371/journal.pone.0065636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. (2014) 42:D68–73. 10.1093/nar/gkt1181 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet. (2010) 87:139–45. 10.1016/j.ajhg.2010.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mishra A, Macgregor S. VEGAS2: Software for more flexible gene-based testing. Twin Res Hum Genet. (2015) 18:86–91. 10.1017/thg.2014.79 [DOI] [PubMed] [Google Scholar]
  • 33.Hecker J, Maaser A, Prokopenko D, Fier HL, Lange C. Reporting correct p values in VEGAS analyses. Twin Res Hum Genet. (2017) 20:257–9. 10.1017/thg.2017.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wojcik GL, Kao WHL, Duggal P. Relative performance of gene- and pathway-level methods as secondary analyses for genome-wide association studies. BMC Genet. (2015) 16:34. 10.1186/s12863-015-0191-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature (2015) 526:68–74. 10.1038/nature15393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sudmant PH, Rausch T, Gardner EJ, Handsaker RE, Abyzov A, Huddleston J, et al. An integrated map of structural variation in 2,504 human genomes. Nature (2015) 526:75. 10.1038/nature15394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Huan T, Rong J, Liu C, Zhang X, Tanriverdi K, Joehanes R, et al. Genome-wide identification of microRNA expression quantitative trait loci. Nat Commun. (2015) 6:6601. 10.1038/ncomms7601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Smalheiser NR, Lugli G, Zhang H, Rizavi H, Cook EH, Dwivedi Y. Expression of microRNAs and other small RNAs in prefrontal cortex in schizophrenia, bipolar disorder and depressed subjects. PLoS ONE (2014) 9:e86469. 10.1371/journal.pone.0086469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, et al. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS ONE (2013) 8:e48814. 10.1371/journal.pone.0048814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Banach E, Dmitrzak-Weglarz M, Pawlak J, Kapelski P, Szczepankiewicz A, Rajewska-Rager A, et al.(2017). Dysregulation of miR-499, miR-708 and miR-1908 during a depression episode in bipolar disorders. Neurosci Lett. 654(Suppl. C):117–9. 10.1016/j.neulet.2017.06.019 [DOI] [PubMed] [Google Scholar]
  • 41.Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. (2012) 13:537–51. 10.1038/nrg3240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 491:119–24. 10.1038/nature11582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kopylov U, Boucher G, Waterman M, Rivers CR, Patel M, Cho JH, et al. Genetic predictors of benign course of ulcerative colitis-a north American inflammatory bowel disease genetics Consortium Study. Inflamm Bowel Dis. (2016) 22:2311–6. 10.1097/mib.0000000000000913 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard BF, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology (2012) 79:2166–70. 10.1212/WNL.0b013e3182759621 [DOI] [PubMed] [Google Scholar]
  • 45.Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol. Ther. (2009) 85:359–61. 10.1038/clpt.2009.6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mason RW, McQueen EG, Keary PJ, James NM. Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. Clin Pharmacokinet. (1978) 3:241–6. [DOI] [PubMed] [Google Scholar]
  • 47.Brown KM, Tracy DK. Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv. Psychopharmacol. (2013) 3:163–76. 10.1177/2045125312471963 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Borel C, Deutsch S, Letourneau A, Migliavacca E, Montgomery SB, Dimas AS, et al. Identification of cis- and trans-regulatory variation modulating microRNA expression levels in human fibroblasts. Genome Res. (2011) 21:68–73. 10.1101/gr.109371.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Zhao XY, Lin JD. Long noncoding RNAs: a new regulatory code in metabolic control. Trends Biochem Sci. (2015) 40:586–96. 10.1016/j.tibs.2015.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Psychiatry are provided here courtesy of Frontiers Media SA

RESOURCES